IPO - Apimeds Pharmaceuticals US, Inc.

Form Type: 10-Q

Filing Date: 2025-05-20

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025045588

Filing Summary: Apimeds Pharmaceuticals US, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2025, indicating a net loss of $402,397 for the quarter and an accumulated deficit of $4,794,321. The company did not report revenues and continues to operate as a clinical stage entity focused on the development of its product, Apitox™, for various medical applications. As of May 19, 2025, it had 11,575,983 shares of common stock outstanding. On May 12, 2025, Apimeds successfully completed its initial public offering of 3,375,000 shares at a price of $4.00 per share, generating $11.9 million in net proceeds. The filing includes comprehensive financial statements showcasing the company's current assets of $259,904 against total liabilities of $2,020,422, primarily related to outstanding accounts payable and convertible notes. The company’s operations and future funding depend heavily on securing regulatory approvals and generating revenue.

Form Type: SCHEDULE 13D

Filing Date: 2025-05-19

Corporate Action: Ipo

Type: New

Accession Number: 000121390025045604

Filing Summary: Apimeds Pharmaceuticals US, Inc. filed a Schedule 13D related to its common stock, par value $0.01 per share. The filing reflects ownership interest from Inscobee Inc. and Apimeds Inc. following a recent initial public offering (IPO) on May 12, 2025, when 3,375,000 shares were sold at $4.00 per share. Inscobee purchased 500,000 shares, totaling $2 million, funded by its working capital. Additionally, convertible promissory notes held by Apimeds Korea and Inscobee, amounting to $772,545 in principal and interest, were converted into 297,133 shares at a conversion price of $2.60 per share, with specific details on the note conversions provided. The statement asserts that all shares are held for investment purposes without intent for a major corporate transformation, although the Reporting Persons maintain rights to adjust their holdings as deemed fit.

Form Type: 8-K

Filing Date: 2025-05-12

Corporate Action: Ipo

Type: New

Accession Number: 000121390025042122

Filing Summary: On May 12, 2025, Apimeds Pharmaceuticals US, Inc. successfully completed its initial public offering (IPO) of 3,375,000 shares of common stock with a par value of $0.01 per share, priced at $4.00 per share. This IPO generated gross proceeds of $13.5 million before underwriting discounts and offering expenses. The company’s Registration Statement on Form S-1 was filed on September 25, 2024, declared effective on February 11, 2025, and included a post-effective amendment filed on May 5, 2025. In connection with the IPO, the Company entered into various agreements, including an Underwriting Agreement with D. Boral Capital LLC and issued Representative’s Warrants for 168,750 shares of Common Stock. Additionally, three convertible promissory notes converted into 297,133 shares of Common Stock at a conversion price of $2.60 per share. The press releases announcing the pricing and closing of the IPO were issued on May 8 and May 12, 2025, respectively.

Form Type: 424B4

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000121390025041193

Filing Summary: Apimeds Pharmaceuticals US, Inc. is conducting an initial public offering, offering 3,375,000 shares of common stock at $4.00 per share, aiming to raise approximately $13.5 million. This IPO comes as the company seeks to establish a public market for its shares, with the stock planned to be listed on NYSE American under the ticker symbol 'APUS'. The company has undergone significant structural changes, including a reverse stock split in February 2025 and significant investment from its major stakeholder, Inscobee Inc., which will retain a controlling interest post-IPO. The funds raised will primarily support clinical trials for Apitox, a biopharmaceutical candidate aimed at treating osteoarthritis and, potentially, multiple sclerosis. Apimeds has positioned itself as a clinical stage biopharmaceutical company, with no prior revenue generated in the US market, focusing on innovative therapies derived from bee venom. The document emphasizes the high risks associated with investment in the company, including potential delays in clinical trials and ongoing financial losses. Apimeds operates under the implications of being an emerging growth company, benefiting from reduced regulatory requirements compared to larger public firms.

Form Type: 8-A12B

Filing Date: 2025-03-03

Corporate Action: Ipo

Type: New

Accession Number: 000121390025019471

Filing Summary: Apimeds Pharmaceuticals US, Inc. is registering shares of common stock, par value $0.01 per share, under Section 12(b) of the Securities Exchange Act of 1934. This registration is part of a planned initial public offering (IPO) following the previously filed Registration Statement on Form S-1 (File No. 333-282324) dated September 25, 2024. The shares are to be listed on NYSE American LLC. The filing signifies a significant step towards becoming a publicly traded entity, allowing the company to raise capital through the sale of its common stock to investors.

Form Type: S-1/A

Filing Date: 2025-02-10

Corporate Action: Ipo

Type: New

Accession Number: 000121390025011555

Filing Summary: Apimeds Pharmaceuticals US, Inc. has filed an S-1/A registration statement with the SEC for its initial public offering (IPO) seeking to sell 4,500,000 shares of common stock with an anticipated price range between $4.00 and $5.00. The company is a clinical stage biopharmaceutical entity focused on developing Apitox, a bee venom-based therapy for osteoarthritis (OA) pain management. The company seeks to list on the NYSE American under the symbol 'APUS.' Apimeds is currently under the control of Inscobee Inc., which owns roughly 70.28% of the company’s shares, reducing to approximately 45.78% post-offering. Apimeds intends to use the proceeds from this IPO to fund a Phase III clinical trial for Apitox and to support advancement in other areas like multiple sclerosis (MS). The document highlights risks related to its clinical development process and indicates that no public market for the company’s shares currently exists. Apimeds has yet to generate revenue from the sale of Apitox in the U.S., and its previous Phase III trials did not meet FDA approval standards, necessitating another Phase III trial.

Form Type: S-1/A

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000121390025010958

Filing Summary: Apimeds Pharmaceuticals US, Inc. has filed an amendment to its registration statement for an initial public offering (IPO) of its common stock. The preliminary prospectus indicates that Apimeds plans to offer 4,500,000 shares of common stock at an anticipated price between $4.00 and $5.00 per share on the NYSE American under the symbol "APUS." This move marks the company's transition to public trading and is contingent upon the successful listing of the shares. Apimeds, a clinical-stage biopharmaceutical firm, is focused on developing Apitox, a bee venom-based toxin intended for treating osteoarthritis and potentially multiple sclerosis. The company seeks to address high unmet medical needs in pain management and enhance patients' quality of life. The filing includes details on existing stockholder interest, proposed sale conditions, and financial projections related to the company’s operations and clinical trials. Notably, Apimeds Korea, a principal stockholder, holds significant voting power in the company which could influence corporate governance. The company aims to initiate a second Phase III trial for Apitox in knee osteoarthritis to meet FDA approval standards, building on prior clinical trial data from South Korea which did not satisfy U.S. standards. The offering is also intended to raise funds for this trial and further development efforts. As an emerging growth company, Apimeds has opted to comply with reduced reporting requirements under federal securities laws.

Form Type: S-1/A

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000121390025007894

Filing Summary: Apimeds Pharmaceuticals US, Inc. is initiating a firm commitment initial public offering (IPO) of 4,500,000 shares of common stock, with an anticipated initial offering price between $4.00 and $5.00. This IPO is contingent upon the successful listing of their common stock on the NYSE American under the ticker symbol 'APUS.' Currently, the company, which specializes in developing a bee venom-based treatment called Apitox for conditions like osteoarthritis (OA) and multiple sclerosis (MS), has not had any public market for its common stock. As part of the offering, existing stockholders have expressed interest in purchasing shares representing up to approximately $6.0 million of the offering, translating to about 33% of the shares to be sold. Apimeds is categorized as an emerging growth company and has opted for reduced public company reporting obligations due to its status. Inscobee Inc., a South Korean parent company, is the major stakeholder, owning around 70.28% of Apimeds, which will reduce to approximately 45.78% post-offering. The offering aims to fund further development of Apitox, specifically pursuing a Phase III trial focused on OA, and to support potential clinical studies in MS. Apimeds also notes significant market potential in the U.S. for OA therapeutics, with the market expected to grow substantially over the next decade. The document outlines various risks associated with the clinical development of their product and the broader impact of chronic conditions on patients' quality of life.

Form Type: S-1/A

Filing Date: 2025-01-10

Corporate Action: Ipo

Type: New

Accession Number: 000121390025002220

Filing Summary: Apimeds Pharmaceuticals US, Inc. is filing Amendment No. 4 to its S-1 registration statement for a proposed initial public offering (IPO) of 3,333,334 shares of common stock. The anticipated IPO price is between $3.00 and $4.00, with plans to list on the NYSE American under the symbol 'APUS'. The company is a clinical stage biopharmaceutical firm focused on developing Apitox, a bee venom-based treatment targeting osteoarthritis (OA) and potentially multiple sclerosis (MS). Currently, Apitox is sold in South Korea as Apitoxin, which has been approved for use against OA in that market since 2003. The company has completed a Phase III trial in Korea, though prior FDA standards were not met in terms of study size and data handling. They are planning a second Phase III trial in the U.S., targeting advanced knee OA patients. Inscobee Inc., a South Korean company, holds a majority of shares, and its influence classifies Apimeds as a controlled company. The document highlights the risks inherent in clinical development and the need for ongoing investment to support their clinical trials and operational activities.